Mallinckrodt is focused on providing innovative therapeutic platforms and comprehensive support services to better enable healthcare professionals to deliver optimised ECP Immunomodulation to patients. The THERAKOS™ CELLEX™ Photopheresis system, the only integrated ECP platform, represents our latest advancement in ECP Immunomodulation technology.
PATIENTS AND CAREGIVERS
Mallinckrodt is committed to improving the lives of patients by offering safe and cost-effective therapies that nurture patients’ own immune systems to fight disease and improve health. [1-5]
Marshall SR. Nat Clin Pract Oncol. 2006 Jun;3(6):302-314.
Bruserud Ø, et al. Cancer Immunol Immunother. 2014;63(8):757-777.
Hart JW, et al. Ther Adv Hematol. 2013;4:320-334.
Suchin KR, et al. J Am Acad Dermatol. 1999;41:980-986.
Das-Gupta E, et al. Bone Marrow Transplant. 2014;49(10):1251-1258.